AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
PROGNOSTIC FACTORS FDR SURVIVAL IN ADVANCED AND METASTATIC UROTHELIALCELL-CARCINOMA (UCC) TREATED WITH CHEMOTHERAPY
Authors: VANDERRIJT CCD SPLINTER TAW SCHMITZ PIM
Citation: Ccd. Vanderrijt et al., PROGNOSTIC FACTORS FDR SURVIVAL IN ADVANCED AND METASTATIC UROTHELIALCELL-CARCINOMA (UCC) TREATED WITH CHEMOTHERAPY, European journal of cancer, 34, 1998, pp. 98-98
NEOADJUVANT CHEMOTHERAPY IN EUROPE
Authors: SPLINTER TAW
Citation: Taw. Splinter, NEOADJUVANT CHEMOTHERAPY IN EUROPE, Annals of oncology, 9, 1998, pp. 13-13
ENHANCED MYELOTOXICITY DUE TO GRANULOCYTE-COLONY-STIMULATING FACTOR ADMINISTRATION UNTIL 48 HOURS BEFORE THE NEXT CHEMOTHERAPY COURSE IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA
Authors: TJANHEIJNEN VCG BIESMA B FESTEN J SPLINTER TAW COX A WAGENER DJT POSTMUS PE
Citation: Vcg. Tjanheijnen et al., ENHANCED MYELOTOXICITY DUE TO GRANULOCYTE-COLONY-STIMULATING FACTOR ADMINISTRATION UNTIL 48 HOURS BEFORE THE NEXT CHEMOTHERAPY COURSE IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA, Journal of clinical oncology, 16(8), 1998, pp. 2708-2714
RANDOMIZED STUDY OF PACLITAXEL-CISPLATIN VERSUS CISPLATIN-TENIPOSIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: GIACCONE G SPLINTER TAW DEBRUYNE C KHO GS LIANES P VANZANDWIJK N PENNUCCI MC SCAGLIOTTI G VANMEERBEECK J VANHOESEL Q CURRAN D SAHMOUD T POSTMUS PE
Citation: G. Giaccone et al., RANDOMIZED STUDY OF PACLITAXEL-CISPLATIN VERSUS CISPLATIN-TENIPOSIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 16(6), 1998, pp. 2133-2141
ETOPOSIDE IN MALIGNANT PLEURAL MESOTHELIOMA - 2 PHASE-II TRIALS OF THE EORTC LUNG-CANCER COOPERATIVE GROUP
Authors: SAHMOUD T POSTMUS PE VANPOTTELSBERGHE C MATTSON K TAMMILEHTO L SPLINTER TAW PLANTING AST SUTEDJA T VANPAWEL J VANZANDWIJK N BAAS P ROOZENDAAL KJ SCHRIJVER M KIRKPATRICK A VANGLABBEKE M ARDIZZONI A GIACCONE G
Citation: T. Sahmoud et al., ETOPOSIDE IN MALIGNANT PLEURAL MESOTHELIOMA - 2 PHASE-II TRIALS OF THE EORTC LUNG-CANCER COOPERATIVE GROUP, European journal of cancer, 33(13), 1997, pp. 2211-2215
13-CIS-RETINOIC ACID AND ALPHA-INTERFERON IN ADVANCED SQUAMOUS-CELL CANCER OF THE ESOPHAGUS
Authors: KOK TC VANDERGAAST A SPLINTER TAW
Citation: Tc. Kok et al., 13-CIS-RETINOIC ACID AND ALPHA-INTERFERON IN ADVANCED SQUAMOUS-CELL CANCER OF THE ESOPHAGUS, European journal of cancer, 33(1), 1997, pp. 165-166
A PHASE-I DOSE-FINDING STUDY OF A BIWEEKLY SCHEDULE OF A FIXED-DOSE OF CISPLATIN WITH INCREASING DOSES OF PACLITAXEL IN PATIENTS WITH ADVANCED ESOPHAGEAL CANCER
Authors: VANDERGAAST A KOK TC VOS R KERKHOFS L SPLINTER TAW
Citation: A. Vandergaast et al., A PHASE-I DOSE-FINDING STUDY OF A BIWEEKLY SCHEDULE OF A FIXED-DOSE OF CISPLATIN WITH INCREASING DOSES OF PACLITAXEL IN PATIENTS WITH ADVANCED ESOPHAGEAL CANCER, Seminars in oncology, 24(6), 1997, pp. 82-85
INTRODUCTION TO THE TREATMENT OF LUNG-CANCER
Authors: SPLINTER TAW
Citation: Taw. Splinter, INTRODUCTION TO THE TREATMENT OF LUNG-CANCER, Seminars in oncology, 24(4), 1997, pp. 1-5
STANDARD VERSUS ALTERNATING NON-CROSS-RESISTANT CHEMOTHERAPY IN EXTENSIVE SMALL-CELL LUNG-CANCER - AN EORTC PHASE-III TRIAL
Authors: POSTMUS PE SCAGLIOTTI G GROEN HJM GOZZELINO F BURGHOUTS JTW CURRAN D SAHMOUD T KIRKPATRICK A GIACCONE G SPLINTER TAW
Citation: Pe. Postmus et al., STANDARD VERSUS ALTERNATING NON-CROSS-RESISTANT CHEMOTHERAPY IN EXTENSIVE SMALL-CELL LUNG-CANCER - AN EORTC PHASE-III TRIAL, European journal of cancer, 32A(9), 1996, pp. 1498-1503
GENITOURINARY GROUP PHASE-II STUDY OF CHEMOTHERAPY IN STAGE T3-4 N0-XM0 TRANSITIONAL-CELL CANCER OF THE BLADDER - PROGNOSTIC FACTOR-ANALYSIS
Authors: SPLINTER TAW PAVONEMACALUSO M JACQMIN D ROBERTS JT CARPENTIER P DEPAUW M SAHMOUD T
Citation: Taw. Splinter et al., GENITOURINARY GROUP PHASE-II STUDY OF CHEMOTHERAPY IN STAGE T3-4 N0-XM0 TRANSITIONAL-CELL CANCER OF THE BLADDER - PROGNOSTIC FACTOR-ANALYSIS, European journal of cancer, 32A(7), 1996, pp. 1129-1134
5-FLUOROURACIL AND FOLINIC ACID IN ADVANCED ADENOCARCINOMA OF THE ESOPHAGUS OR ESOPHAGOGASTRIC JUNCTION AREA
Authors: KOK TC VANDERGAAST A SPLINTER TAW
Citation: Tc. Kok et al., 5-FLUOROURACIL AND FOLINIC ACID IN ADVANCED ADENOCARCINOMA OF THE ESOPHAGUS OR ESOPHAGOGASTRIC JUNCTION AREA, Annals of oncology, 7(5), 1996, pp. 533-534
TUMOR-MARKER AIDED DISCRIMINATION BETWEEN DISEASE STAGES IN SMALL-CELL LUNG-CANCER (SCLC)
Authors: JORGENSEN LGM OSTERLIND K GOMM SA HERNANDEZ JR JOHNSON PWM LOBER J SPLINTER TAW SZTURMOWICZ M
Citation: Lgm. Jorgensen et al., TUMOR-MARKER AIDED DISCRIMINATION BETWEEN DISEASE STAGES IN SMALL-CELL LUNG-CANCER (SCLC), Journal of tumor marker oncology, 11(4), 1996, pp. 7-14
2 SCHEDULES OF TENIPOSIDE WITH OR WITHOUT CISPLATIN IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER LUNG-CANCER COOPERATIVE GROUP
Authors: SPLINTER TAW SAHMOUD T FESTEN J VANZANDWIJK N SORENSON S CLERICO M BURGHOUTS J DAUTZENBERG B KHO GS KIRKPATRICK A GIACCONE G
Citation: Taw. Splinter et al., 2 SCHEDULES OF TENIPOSIDE WITH OR WITHOUT CISPLATIN IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER LUNG-CANCER COOPERATIVE GROUP, Journal of clinical oncology, 14(1), 1996, pp. 127-134
PACLITAXEL AND CARBOPLATIN AS NEOADJUVANT CHEMOTHERAPY IN OPERABLE (STAGE-I AND STAGE-II) AND LOCALLY ADVANCED (STAGE IIIA-N2) NONSMALL CELL LUNG-CANCER
Authors: SPLINTER TAW
Citation: Taw. Splinter, PACLITAXEL AND CARBOPLATIN AS NEOADJUVANT CHEMOTHERAPY IN OPERABLE (STAGE-I AND STAGE-II) AND LOCALLY ADVANCED (STAGE IIIA-N2) NONSMALL CELL LUNG-CANCER, Seminars in oncology, 23(6), 1996, pp. 59-61
DISCUSSION - LUNG-CANCER
Authors: CARNEY DN BUNN PA BELANI CP",GIACCONE,"SHEPHERD FA CALVERT AH COMIS RL SPLINTER TAW ETTINGER DS JOHNSON DH LANGER CJ GRECO FA HAINSWORTH JD BONOMI P CURRAN WJ CHOY H GLANTZ MJ
Citation: Dn. Carney et al., DISCUSSION - LUNG-CANCER, Seminars in oncology, 23(6), 1996, pp. 140-147
RESULTS OF THE PHASE-II EORTC STUDY COMPARING PACLITAXEL CISPLATIN WITH TENIPOSIDE/CISPLATIN IN PATIENTS WITH NONSMALL CELL LUNG-CANCER/
Authors: POSTMUS PE GIACCONE G DEBRUYNE C SAHMOUD T SPLINTER TAW VANZANDWIJK N
Citation: Pe. Postmus et al., RESULTS OF THE PHASE-II EORTC STUDY COMPARING PACLITAXEL CISPLATIN WITH TENIPOSIDE/CISPLATIN IN PATIENTS WITH NONSMALL CELL LUNG-CANCER/, Seminars in oncology, 23(5), 1996, pp. 10-13
CISPLATIN AND ETOPOSIDE IN ESOPHAGEAL CANCER - A PHASE-II STUDY
Authors: KOK TC VANDERGAAST A DEES J EYKENBOOM WMH VANOVERHAGEN H STOTER G TILANUS HW SPLINTER TAW
Citation: Tc. Kok et al., CISPLATIN AND ETOPOSIDE IN ESOPHAGEAL CANCER - A PHASE-II STUDY, British Journal of Cancer, 74(6), 1996, pp. 980-984
SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS
Authors: JORGENSEN LGM OSTERLIND K GENOLLA J GOMM SA HERNANDEZ JR JOHNSON PWM LOBER J SPLINTER TAW SZTURMOWICZ M
Citation: Lgm. Jorgensen et al., SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS, British Journal of Cancer, 74(3), 1996, pp. 463-467
SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS (VOL 74, PG 463, 1996)
Authors: JORGENSEN LGM OSTERLIND K GENOLLA J GOM SA HERNANDEZ JR JOHNSON PWM LOBER J SPLINTER TAW SZTURMOWICZ M
Citation: Lgm. Jorgensen et al., SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS (VOL 74, PG 463, 1996), British Journal of Cancer, 74(12), 1996, pp. 2043-2043
DISEASE MONITORING BY THE TUMOR-MARKERS CYFRA-21.1 AND TPA IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
Authors: VANDERGAAST A KOK TC KHO GS BLIJENBERG BG SPLINTER TAW
Citation: A. Vandergaast et al., DISEASE MONITORING BY THE TUMOR-MARKERS CYFRA-21.1 AND TPA IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER, European journal of cancer, 31A(11), 1995, pp. 1790-1793
PROBLEMS WITH THE EVALUATION OF RESPONSE AFTER INDUCTION CHEMOTHERAPYIN BREAST-CANCER
Authors: MANNESSE CK VANPEL R VANSPENGLER J VANEIJCK CH SPLINTER TAW
Citation: Ck. Mannesse et al., PROBLEMS WITH THE EVALUATION OF RESPONSE AFTER INDUCTION CHEMOTHERAPYIN BREAST-CANCER, European journal of cancer, 31A(11), 1995, pp. 1886-1887
SERUM TUMOR-MARKERS AND MANAGEMENT OF NON-SMALL-CELL LUNG-CANCER
Authors: SPLINTER TAW
Citation: Taw. Splinter, SERUM TUMOR-MARKERS AND MANAGEMENT OF NON-SMALL-CELL LUNG-CANCER, Lung cancer, 13(2), 1995, pp. 177-179
MITOXANTRONE IN METASTATIC APUDOMAS - A PHASE-II STUDY OF THE EORTC GASTROINTESTINAL CANCER COOPERATIVE GROUP
Authors: NEIJT JP LACAVE AJ SPLINTER TAW TAAL BG VEENHOF CHN SAHMOUD T LIPS CJM
Citation: Jp. Neijt et al., MITOXANTRONE IN METASTATIC APUDOMAS - A PHASE-II STUDY OF THE EORTC GASTROINTESTINAL CANCER COOPERATIVE GROUP, British Journal of Cancer, 71(1), 1995, pp. 106-108
PROGNOSTIC-SIGNIFICANCE OF TISSUE POLYPEPTIDE-SPECIFIC ANTIGEN (TPS) IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER
Authors: VANDERGAAST A SCHOENMAKERS CHH KOK TC BLIJENBERG BG HOP WCJ SPLINTER TAW
Citation: A. Vandergaast et al., PROGNOSTIC-SIGNIFICANCE OF TISSUE POLYPEPTIDE-SPECIFIC ANTIGEN (TPS) IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER, European journal of cancer, 30A(12), 1994, pp. 1783-1786
PHASE-II STUDY OF CARBOPLATIN AND ETOPOSIDE AS A FIRST-LINE REGIMEN IN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: VANDERGAAST A BONTENBAL M PLANTING AST KOK TC SPLINTER TAW
Citation: A. Vandergaast et al., PHASE-II STUDY OF CARBOPLATIN AND ETOPOSIDE AS A FIRST-LINE REGIMEN IN PATIENTS WITH METASTATIC BREAST-CANCER, Annals of oncology, 5(9), 1994, pp. 858-860
Risultati: 1-25 | 26-31